Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, and Hepatitis Viruses Studies and Epidemiology.
Comment on AASLD ISDA Practice Guideline on treatment of chronic hepatitis B (2025 Update).
Accelerated impact of alcohol-associated hepatitis on healthcare utilisation during the COVID-19 pandemic.
A Costing Analysis of a Nurse- and Peer-Led Mobile Model of Hepatitis C Care Adjacent to the Community Corrections Setting.
Safety, feasibility, and dose-dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof-of-concept studies.
The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus.
Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study
Early-Stage Australian HCC Patients Treated at Tertiary Centres Show Comparable Survival Across Metropolitan and Non-Metropolitan Residency
"Quick, simple, and friendly": Understanding the acceptability and accessibility of a nurse and peer-led, mobile model of hepatitis C care adjacent to community corrections in Australia
Strengths and limitations of urinary sugar testing: an observational study of intestinal permeability and absorption in adults and children in Zambia and Tanzania with reference to mucosal biopsies
Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis
Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility
Individualizing the Approach to Stopping Nucleos(t)ide Analogs: Can We Use a Low HBsAg Threshold to Predict a High Chance of Functional Cure and Minimal Risk of Hepatic Decompensation?
Impact of an Automated Population-Level Cirrhosis Screening Program Using Common Pathology Tests on Rates of Cirrhosis Diagnosis and Linkage to Specialist Care (CAPRISE): Protocol for a Pilot Prospective Single-Arm Intervention Study.
Impact of an Automated Population-Level Cirrhosis Screening Program Using Common Pathology Tests on Rates of Cirrhosis Diagnosis and Linkage to Specialist Care (CAPRISE): Protocol for a Pilot Prospective Single-Arm Intervention Study (Preprint)
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
A novel point-of-care test for cirrhosis based on dimeric to monomeric IgA ratio in blood: a pilot cohort study.
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
Australian consensus recommendations for the management of hepatitis B
Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus
Understanding how to live with hepatitis B: a qualitative investigation of peer advice for Chinese people living with hepatitis B in Australia.
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement
Australian recommendations for the management of hepatocellular carcinoma: a consensus statement
Increasing prevalence of primary biliary cholangitis in Victoria, Australia.
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
A global scientific strategy to cure hepatitis B
Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030
Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials